Rheumatoid arthritis

Visiongain Report Offers Transformative Insights on $47bn Rheumatoid Arthritis Market

Retrieved on: 
Friday, January 11, 2019
Medicine, Health, RTT, Rheumatology, Arthritis, Autoimmune diseases, Biotechnology, Rheumatoid arthritis, Biopharmaceutical

The global rheumatoid arthritis drugs market will reach $47bn in 2024.

Key Points: 
  • The global rheumatoid arthritis drugs market will reach $47bn in 2024.
  • In 2018, the Biologics submarket held 87% of the Global Rheumatoid Arthritis Drugs market.
  • The 232-page report provides clear detailed insight into the rheumatoid arthritis market.
  • Forecast of the Global Rheumatoid Arthritis market by Submarket:
    Forecast of the leading drugs in the Global Rheumatoid Arthritis market:

Visiongain Report Offers Transformative Insights on $47bn Rheumatoid Arthritis Market

Retrieved on: 
Friday, January 11, 2019
Medicine, Health, RTT, Rheumatology, Arthritis, Autoimmune diseases, Biotechnology, Rheumatoid arthritis, Biopharmaceutical

The global rheumatoid arthritis drugs market will reach $47bn in 2024.

Key Points: 
  • The global rheumatoid arthritis drugs market will reach $47bn in 2024.
  • In 2018, the Biologics submarket held 87% of the Global Rheumatoid Arthritis Drugs market.
  • The 232-page report provides clear detailed insight into the rheumatoid arthritis market.
  • Forecast of the Global Rheumatoid Arthritis market by Submarket:
    Forecast of the leading drugs in the Global Rheumatoid Arthritis market:

The global PEGylated protein therapeutics market was valued at $10,388 million in 2017, and is estimated to reach at $17,813 million by 2025, registering a CAGR of 6.9% from 2018 to 2025

Retrieved on: 
Friday, December 14, 2018
Medicine, RTT, Biotechnology, Health, PEGylation, Pharmacokinetics, Arthritis, Chronic condition, Rheumatoid arthritis

The global PEGylated protein therapeutics market was valued at $10,388 million in 2017, and is estimated to reach at $17,813 million by 2025, registering a CAGR of 6.9% from 2018 to 2025.

Key Points: 
  • The global PEGylated protein therapeutics market was valued at $10,388 million in 2017, and is estimated to reach at $17,813 million by 2025, registering a CAGR of 6.9% from 2018 to 2025.
  • The factors that propel the PEGylated protein therapeutics market growth include high prevalence of chronic diseases, such as cancer, kidney diseases, and rheumatoid arthritis.
  • The global PEGylated protein therapeutics market is segmented based on product type, application, sales channel, and region.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)

Retrieved on: 
Thursday, December 13, 2018
Medicine, Anatomy, Autoimmune diseases, RTT, Health, Connective tissue diseases, Rheumatology, Cutaneous lupus erythematosus, Systemic lupus erythematosus, Autoimmunity, Lupus erythematosus, Rheumatoid arthritis

"As part of the Fast Track designation, we will work closely with the FDA to further explore baricitinib's potential as a treatment that can provide meaningful improvements for people with SLE."

Key Points: 
  • "As part of the Fast Track designation, we will work closely with the FDA to further explore baricitinib's potential as a treatment that can provide meaningful improvements for people with SLE."
  • Baricitinib is approved in over 50 countries globally as OLUMIANT for the treatment of adults with rheumatoid arthritis.
  • Carefully consider the risks and benefits of Olumiant prior to initiating therapy in patients with chronic or recurrent infection.
  • Systemic lupus erythematosus (SLE) is a chronic, multi-organ autoimmune disease that can cause widespread tissue and organ damage.

The Global Market for Rheumatoid Arthritis Drugs (2018-2022): Analysis by Type of Molecule, Type of RA, Region and Vendor

Retrieved on: 
Friday, December 7, 2018
Medicine, Health, RTT, Rheumatology, Arthritis, Autoimmune diseases, Biotechnology, Rheumatoid arthritis, Disease-modifying antirheumatic drug, Biopharmaceutical, Nonsteroidal anti-inflammatory drug, Psoriatic arthritis

The "Global Rheumatoid Arthritis Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Rheumatoid Arthritis Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • The rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.
  • The use of biologics and biosimilars for the treatment of RA is likely to help the market grow.
  • Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.

The Rheumatoid Arthritis Drugs Market will register a CAGR of close to 8% by 2022

Retrieved on: 
Tuesday, December 4, 2018
Medicine, Health, Biotechnology, RTT, Arthritis, Rheumatology, Specialty drugs, Biopharmaceutical, Rheumatoid arthritis, Biosimilar, Synovectomy

Technavio's analysts have predicted that the rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.

Key Points: 
  • Technavio's analysts have predicted that the rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.
  • For the detailed list of factors that will drive and challenge the growth of the rheumatoid arthritis drugs market during the 2018-2022, view our report.
  • Factors such as the use of biologics and biosimilars for the treatment of RA and increasing need for affordable biologics for rheumatoid arthritis, will provide considerable growth opportunities to rheumatoid arthritis drugs manufactures.
  • Many established rheumatoid arthritis drug companies are vying for their share of the global rheumatoid arthritis drugs market, and players must differentiate themselves to gain vital traction over their competitors.'

First Berlin Equity Research Publishes Updated Independent Analysis of Cyxone

Retrieved on: 
Monday, December 3, 2018
Medicine, RTT, Health, Immunology, Arthritis, Autoimmunity, Rheumatoid arthritis

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA).

Key Points: 
  • Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA).
  • The company's drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typically associated with various immune-related disorders.
  • The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program.
  • Cyxone's Certified Adviser on the Nasdaq First North is Mangold Fondkommission AB, +46-(0)8-503-015-50.

First Berlin Equity Research Publishes Updated Independent Analysis of Cyxone

Retrieved on: 
Monday, December 3, 2018
Medicine, RTT, Health, Immunology, Arthritis, Autoimmunity, Rheumatoid arthritis

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA).

Key Points: 
  • Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA).
  • The company's drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typically associated with various immune-related disorders.
  • The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program.
  • Cyxone's Certified Adviser on the Nasdaq First North is Mangold Fondkommission AB, +46-(0)8-503-015-50.

Largest Michigan Medicare Plans Receive Failing Grades For Coverage Of Autoimmune Disease Medications

Retrieved on: 
Thursday, November 29, 2018
Medicine, Clinical medicine, Autoimmune diseases, Immunology, RTT, Psoriasis, Rheumatology, Arthritis, Psoriatic arthritis, Rheumatoid arthritis, Autoimmunity, Crohn's disease

They include Crohn's disease, multiple sclerosis, psoriasis, psoriatic arthritis, and rheumatoid arthritis.

Key Points: 
  • They include Crohn's disease, multiple sclerosis, psoriasis, psoriatic arthritis, and rheumatoid arthritis.
  • For each of the five autoimmune conditions studied, the average grade was an F for the top 25 Medicare plans, including plans associated with national insurers like AARP, Aetna, Cigna, and Humana.
  • It follows the release last month of a report card that evaluated the largest 25 private and public health plans in Michigan according to their access restrictions on medications for autoimmune conditions.
  • That report evaluated the top 25 private and Medicare health plans in Michigan based on their overall access to medicines indicated for each of five autoimmune conditions (Crohn's disease, multiple sclerosis, psoriasis, psoriatic arthritis, and rheumatoid arthritis).

First Berlin Equity Research Publishes Independent Analysis of Cyxone

Retrieved on: 
Wednesday, October 31, 2018
Medicine, RTT, Clinical medicine, Health, Immunology, Arthritis, Autoimmunity, Rheumatoid arthritis

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA).

Key Points: 
  • Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA).
  • The company's drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typically associated with various immune-related disorders.
  • The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program.
  • Cyxone's Certified Adviser on the Nasdaq First North is Mangold Fondkommission AB, +46 (0)8-503 015 50.